ArticleCancer research2021
Open access · bronzeAbstract read
In one paragraph
Article in Cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 51 citations in OpenAlex.
- TET2 loss triggers ssDNA gap accumulation and heightened PARP inhibitor sensitivity.Nature communications · 2026Article
- Hematopoietic Aging and Leukemia: Mechanistic and Therapeutic Insights.International journal of molecular sciences · 2026Review
- Polθ activity modulates sensitivity to standard therapies in DNMT3A-deficient leukemia.Cell reports. Medicine · 2026Article
- Clonal hematopoiesis mutation is associated with risk of incident lung cancer and death.GeroScience · 2026Article
- The need for speed: drivers and consequences of accelerated replication forks.Communications biology · 2025Review
- Article
- Article
- Non-canonical functions of DNMT3A in hematopoietic stem cells regulate telomerase activity and genome integrity.Cell stem cell · 2025Article
- Clonal hematopoiesis in myeloid malignancies and solid tumors.Nature cancer · 2025Review
- Clinical approaches to overcome PARP inhibitor resistance.Molecular cancer · 2025Review
- Significance of targeting DNMT3A mutations in AML.Annals of hematology · 2025Review
- Neomorphic leukemia-derived mutations in the TET2 enzyme induce genome instability via a substrate shift from 5-methylcytosine to thymine.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- TET2 cascade: a novel regulator of chromatin structure and leukaemogenesis.Signal transduction and targeted therapy · 2025Article
- TET2 mutation in acute myeloid leukemia: biology, clinical significance, and therapeutic insights.Clinical epigenetics · 2024Review
- TET2 germline variants promote kidney disease by impairing DNA repair and activating cytosolic nucleotide sensors.Nature communications · 2024Article
- Star wars against leukemia: attacking the clones.Leukemia · 2024Review
- PARG is essential for Polθ-mediated DNA end-joining by removing repressive poly-ADP-ribose marks.Nature communications · 2024Article
- Article
- R-Loop Accumulation in Spliceosome Mutant Leukemias Confers Sensitivity to PARP1 Inhibition by Triggering Transcription-Replication Conflicts.Cancer research · 2024Article
- TET2 mutations contribute to adverse prognosis in acute myeloid leukemia (AML): results from a comprehensive analysis of 502 AML cases and the Beat AML public database.Clinical and experimental medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors at 16 institutions in 6 countries.
Silvia MaifredeFels Cancer Institute for Personalized Medicine and Sol Sherry Thrombosis Research Center, Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania.
Bac Viet LeFels Cancer Institute for Personalized Medicine and Sol Sherry Thrombosis Research Center, Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania.ORCID 0000-0001-5077-8994
Margaret Nieborowska-SkorskaFels Cancer Institute for Personalized Medicine and Sol Sherry Thrombosis Research Center, Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania.
Konstantin GolovineFels Cancer Institute for Personalized Medicine and Sol Sherry Thrombosis Research Center, Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania.
Katherine Sullivan-ReedFels Cancer Institute for Personalized Medicine and Sol Sherry Thrombosis Research Center, Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania.
Wangisa M B DunuwilleDepartment of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, Missouri.
Joseph NacsonDepartment of Pathology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Michael HulseFels Cancer Institute for Personalized Medicine, Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania.ORCID 0000-0002-6691-365X
Kelsey KeithCoriell Institute for Medical Research, Camden, New Jersey.ORCID 0000-0002-7451-5117
Jozef MadzoCoriell Institute for Medical Research, Camden, New Jersey.ORCID 0000-0001-6607-1213
Lisa Beatrice CarusoFels Cancer Institute for Personalized Medicine, Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania.
Zachary GazzeFels Cancer Institute for Personalized Medicine and Sol Sherry Thrombosis Research Center, Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania.ORCID 0000-0002-5929-7414
Zhaorui LianCoriell Institute for Medical Research, Camden, New Jersey.ORCID 0000-0001-9309-6379
Antonella PadellaIRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori," Meldola, Italy.ORCID 0000-0001-9991-992X
Kumaraswamy N ChitralaFels Cancer Institute for Personalized Medicine, Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania.
Boris A BartholdyDepartment of Cell Biology, Albert Einstein College of Medicine, Bronx, New York.ORCID 0000-0002-7401-8591
Ksenia Matlawska-WasowskaDivision of Hematology-Oncology, Department of Pediatrics, University of New Mexico Health Sciences Center, Albuquerque, New Mexico.ORCID 0000-0002-9903-5793
Daniela Di MarcantonioResearch Institute of Fox Chase Cancer Center, Immune Cell Development and Host Defense, Philadelphia, Pennsylvania.
Giorgia SimonettiIRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori," Meldola, Italy.
Georg GreinerDepartment of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-0917-4117
Stephen M SykesResearch Institute of Fox Chase Cancer Center, Immune Cell Development and Host Defense, Philadelphia, Pennsylvania.
Peter ValentDivision of Hematology and Hemostaseology and Ludwig-Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
Elisabeth M PaiettaAlbert Einstein College of Medicine-Montefiore Medical Center, Bronx, New York.
Martin S TallmanCenter for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York.
Hugo F FernandezMoffitt Malignant Hematology and Cellular Therapy at Memorial Healthcare System, Pembroke Pines, Florida.
Mark R LitzowDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Mark D MindenPrincess Margaret Cancer Center, Ontario Cancer Institute, Toronto, Ontario, Canada.
Jian HuangCoriell Institute for Medical Research, Camden, New Jersey.
Giovanni MartinelliIRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori," Meldola, Italy.
George S VassiliouWellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.
Italo TemperaFels Cancer Institute for Personalized Medicine, Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania.
Katarzyna PiwockaNencki Institute of Experimental Biology, Warsaw, Poland.
Neil JohnsonDepartment of Pathology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Grant A ChallenDepartment of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, Missouri. tskorski@temple.edu grantchallen@wustl.edu.ORCID 0000-0003-4669-8814
Tomasz SkorskiFels Cancer Institute for Personalized Medicine and Sol Sherry Thrombosis Research Center, Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania. tskorski@temple.edu grantchallen@wustl.edu.
Temple University · USCoriell Institute For Medical Research · USFox Chase Cancer Center · USIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori · ITInstytut Biologii Doświadczalnej im. Marcelego Nenckiego · PLWashington University in St. Louis · USAlbert Einstein College of Medicine · USLudwig Boltzmann Institute for Lung Health · ATMayo Clinic · USMedical University of Vienna · ATMemorial Healthcare System · USMemorial Sloan Kettering Cancer Center · USMontefiore Medical Center · USOntario Institute for Cancer Research · CAUniversity of New Mexico · USWellcome/MRC Cambridge Stem Cell Institute · GB
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MProject-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer · 2014 to 2026
$167.6MTumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Luis J Montaner · 1985 to 2026
$75.9MECOG-ACRIN Biospecimen Bank to Support NCTNU24CA196172 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI STANLEY R. HAMILTON, Scott D Jewell · 2015 to 2026
$41.1MMontefiore Academic Community NCORP ProgramUG1CA189859 · NCI · MONTEFIORE MEDICAL CENTER (BRONX, NY) · PI Balazs Halmos, Della Makower · 2014 to 2026
$10.8MTRAINING PROGRAM IN CANCER RESEARCHT32CA009035 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI CHERNOFF, JONATHAN · 1985 to 2020
$10.5MNetwork Lead Academic Participating Site: Memorial Sloan Kettering Cancer CenterUG1CA233290 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CAROL AGHAJANIAN, Darren Feldman · 2019 to 2026
$10.2MNCI, National Clinical Trials Network Lead Academic Participating Site (LAPS) UG1 (funded extension)UG1CA232760 · NCI · MAYO CLINIC ROCHESTER · PI Judy Caroline Boughey, Aaron Scott Mansfield · 2019 to 2026
$8.5MTargeting DNA repair to eradicate TKi-refractory/resistant CML and Ph+ALLR01CA186238 · NCI · TEMPLE UNIV OF THE COMMONWEALTH · PI SKORSKI, TOMASZ · 2014 to 2024
$4.5MCompensatory Mechanisms that Promote Homologous Recombination in BRCA1 Mutant CancersR01CA214799 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Neil Johnson · 2017 to 2026
$4.3MAML mutation-guided drugging of DNA repairR01CA237286 · NCI · TEMPLE UNIV OF THE COMMONWEALTH · PI MAZIN, ALEXANDER V, SKORSKI, TOMASZ · 2020 to 2024
$2.8MMPN-inducing mutations as biomarkers of synthetic lethalityR01CA247707 · NCI · TEMPLE UNIV OF THE COMMONWEALTH · PI SKORSKI, TOMASZ · 2020 to 2024
$2.1MNCI NIH HHS P30 CA008748NCI NIH HHS P30 CA010815NCI NIH HHS R01 CA186238NCI NIH HHS R01 CA214799NCI NIH HHS R01 CA227830NCI NIH HHS R01 CA237165NCI NIH HHS R01 CA237286NCI NIH HHS R01 CA244044NCI NIH HHS R01 CA247707NCI NIH HHS T32 CA009035NCI NIH HHS U10 CA180820NCI NIH HHS U24 CA196172NCI NIH HHS UG1 CA189859NCI NIH HHS UG1 CA232760NCI NIH HHS UG1 CA233290NHLBI NIH HHS R01 HL147978NIDDK NIH HHS R01 DK102428NIGMS NIH HHS R01 GM124449NIGMS NIH HHS R01 GM135293
Abstract
Somatic variants in
Indexed as
DNA RepairMutationAnimalsCell Line, TumorCRISPR-Cas SystemsDioxygenasesDisease Models, AnimalDNA-Binding ProteinsDNA Methyltransferase 3ADose-Response Relationship, DrugDrug Resistance, NeoplasmGene Knockdown TechniquesGenotypeHumansLeukemiaMiceDioxygenasesDNA-Binding ProteinsDNA Methyltransferase 3ADNMT3A protein, humanPoly(ADP-ribose) Polymerase InhibitorsTET2 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.